


# STUDY OF CARDIOVASCULAR TOXICITY ASSOCIATED WITH IBRUTINIB TREATMENT

R. TAMAYO BERMEJO, JC. DEL RIO VALENCIA, C. ORTEGA DE LA CRUZ, I. MUÑOZ CASTILLO.  
REGIONAL UNIVERSITY HOSPITAL OF MÁLAGA, PHARMACY, MÁLAGA, SPAIN.




## ➤ Background:

Ibrutinib treatment has been associated with the development of unwanted cardiovascular (CV) and bleeding events, which may lead to the loss of a line of treatment in patients with so few therapeutic options.

## ➤ Objective:


To evaluate the rate of events related to cardiovascular toxicity during treatment with ibrutinib.

## ➤ Material and methods:




## ➤ Results:


66 patients      72.7 years      68.2% men




Duration 22.6 months [7-80]



Dose reduced 2 patients      Suspended 2 patients



63.6% continue      21.2% progressed      15.5% died



## ➤ Conclusion:

The following study shows that 65% of patients do not develop any type of cardiovascular toxicity. Only a small percentage of patients need a dose reduction or suspension of treatment due to cardiovascular adverse events, requiring a multidisciplinary approach in the proper management of the drug.